Gomco Pharma is a growing pharmaceutical business based in Chandigarh, offering Respiratory Range PCD Pharma Franchise opportunities across India. Established in 2022, the company operates as a wholesaler, exporter, and service provider in the pharmaceutical sector, with a focus on providing quality pharmaceutical products and reliable franchise solutions.
The company offers respiratory-focused products through its PCD franchise portfolio, including cough syrups and other formulations designed for respiratory and cold-related healthcare requirements. Its product listings include formulations containing ingredients such as Ambroxol, Levosalbutamol, Guaiphenesin, Terbutaline, and Menthol. Gomco Pharma also offers tablets, capsules, syrups, injections, softgels, ointments, sachets, and other pharmaceutical dosage forms across multiple therapeutic segments.
Gomco Pharma provides PCD franchise opportunities with district-wise or monopoly rights, promotional materials, product availability, and PAN-India business support. Its broader product portfolio covers respiratory, cardiac-diabetic, gastrointestinal, neurological, pediatric, gynecology, orthopedic, antibiotic, and other therapeutic segments.
With a customer-focused approach, transparent business practices, competitive product offerings, and dedicated franchise support, Gomco Pharma continues to develop its presence in the Indian pharmaceutical market. Its Respiratory Range makes it a suitable option for entrepreneurs looking to enter the respiratory healthcare segment through a PCD pharma franchise business.
Gomco Pharma emphasizes quality-focused pharmaceutical sourcing and follows documented quality standards and certifications associated with its listed PCD products and business offerings.
To provide quality pharmaceutical products and reliable PCD franchise opportunities while supporting healthcare entrepreneurs through professional service, transparent business practices, and consistent product availability.
To become a trusted pharmaceutical franchise partner in India by expanding its therapeutic portfolio, strengthening distribution networks, and creating long-term business relationships.
N/A